Durvalumab companion diagnostic - MedImmune/Ventana Medical Systems

Drug Profile

Durvalumab companion diagnostic - MedImmune/Ventana Medical Systems

Alternative Names: MEDI-4736 companion diagnostic - MedImmune/Ventana Medical Systems; VENTANA PD-L1 (SP 263) Assay

Latest Information Update: 11 May 2017

Price : $50

At a glance

  • Originator MedImmune; Ventana Medical Systems
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Urogenital cancer
  • Clinical Phase Unknown Head and neck cancer; Non-small cell lung cancer

Most Recent Events

  • 02 May 2017 Launched for Urogenital cancer (Diagnosis) in USA (unspecified route)
  • 01 May 2017 Registered for Urogenital cancer (Diagnosis) in USA (unspecified route)
  • 31 May 2015 Clinical trials in Head and neck cancer (Diagnosis) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top